Tags

Type your tag names separated by a space and hit enter

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.
Neuropsychopharmacology. 2010 Sep; 35(10):2072-82.N

Abstract

Paliperidone palmitate is a long-acting injectable antipsychotic agent. This 13-week, multicenter, randomized (1 : 1 : 1 : 1), double-blind, parallel-group study evaluated the efficacy, safety, and tolerability of fixed 25, 50, and 100 milligram equivalent (mg equiv.) doses of paliperidone palmitate vs placebo administered as gluteal injections on days 1 and 8, then every 4 weeks (days 36 and 64) in 518 adult patients with schizophrenia. The intent-to-treat analysis set (N=514) was 67% men and 67% White, with a mean age of 41 years. All paliperidone palmitate dose groups showed significant improvement vs placebo in the Positive and Negative Syndrome Scale (PANSS) total score (primary efficacy measure; 25 and 50 mg equiv., p=0.02; 100 mg equiv., p<0.001), as well as Clinical Global Impression Severity scores (p< or =0.006) and PANSS negative and positive symptom Marder factor scores (p< or =0.04). The Personal and Social Performance scale showed no significant difference between treatment groups. The overall incidence of treatment-emergent adverse events was similar between groups. Parkinsonism, the most frequently reported extrapyramidal symptom, was reported at similar rates for placebo (5%) and paliperidone palmitate (5-6% across doses). The mean body mass index and mean weight showed relatively small dose-related increases during paliperidone palmitate treatment. Investigator-evaluated injection-site pain, swelling, redness, and induration were similar across treatment groups; scores for patient-evaluated injection-site pain (visual analog scale) were similar across groups and diminished with time. All doses of once-monthly paliperidone palmitate were efficacious and generally tolerated, both locally and systemically. Paliperidone palmitate offers the potential to improve outcomes in adults with symptomatic schizophrenia.

Authors+Show Affiliations

Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267, USA. henry.nasrallah@uc.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20555312

Citation

Nasrallah, Henry A., et al. "A Controlled, Evidence-based Trial of Paliperidone Palmitate, a Long-acting Injectable Antipsychotic, in Schizophrenia." Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, vol. 35, no. 10, 2010, pp. 2072-82.
Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35(10):2072-82.
Nasrallah, H. A., Gopal, S., Gassmann-Mayer, C., Quiroz, J. A., Lim, P., Eerdekens, M., Yuen, E., & Hough, D. (2010). A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, 35(10), 2072-82. https://doi.org/10.1038/npp.2010.79
Nasrallah HA, et al. A Controlled, Evidence-based Trial of Paliperidone Palmitate, a Long-acting Injectable Antipsychotic, in Schizophrenia. Neuropsychopharmacology. 2010;35(10):2072-82. PubMed PMID: 20555312.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. AU - Nasrallah,Henry A, AU - Gopal,Srihari, AU - Gassmann-Mayer,Cristiana, AU - Quiroz,Jorge A, AU - Lim,Pilar, AU - Eerdekens,Mariëlle, AU - Yuen,Eric, AU - Hough,David, Y1 - 2010/06/16/ PY - 2010/6/18/entrez PY - 2010/6/18/pubmed PY - 2010/12/14/medline SP - 2072 EP - 82 JF - Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology JO - Neuropsychopharmacology VL - 35 IS - 10 N2 - Paliperidone palmitate is a long-acting injectable antipsychotic agent. This 13-week, multicenter, randomized (1 : 1 : 1 : 1), double-blind, parallel-group study evaluated the efficacy, safety, and tolerability of fixed 25, 50, and 100 milligram equivalent (mg equiv.) doses of paliperidone palmitate vs placebo administered as gluteal injections on days 1 and 8, then every 4 weeks (days 36 and 64) in 518 adult patients with schizophrenia. The intent-to-treat analysis set (N=514) was 67% men and 67% White, with a mean age of 41 years. All paliperidone palmitate dose groups showed significant improvement vs placebo in the Positive and Negative Syndrome Scale (PANSS) total score (primary efficacy measure; 25 and 50 mg equiv., p=0.02; 100 mg equiv., p<0.001), as well as Clinical Global Impression Severity scores (p< or =0.006) and PANSS negative and positive symptom Marder factor scores (p< or =0.04). The Personal and Social Performance scale showed no significant difference between treatment groups. The overall incidence of treatment-emergent adverse events was similar between groups. Parkinsonism, the most frequently reported extrapyramidal symptom, was reported at similar rates for placebo (5%) and paliperidone palmitate (5-6% across doses). The mean body mass index and mean weight showed relatively small dose-related increases during paliperidone palmitate treatment. Investigator-evaluated injection-site pain, swelling, redness, and induration were similar across treatment groups; scores for patient-evaluated injection-site pain (visual analog scale) were similar across groups and diminished with time. All doses of once-monthly paliperidone palmitate were efficacious and generally tolerated, both locally and systemically. Paliperidone palmitate offers the potential to improve outcomes in adults with symptomatic schizophrenia. SN - 1740-634X UR - https://www.unboundmedicine.com/medline/citation/20555312/A_controlled_evidence_based_trial_of_paliperidone_palmitate_a_long_acting_injectable_antipsychotic_in_schizophrenia_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20555312/ DB - PRIME DP - Unbound Medicine ER -